Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance
Restricted accessOtherFirst published online December, 2010
Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance
Brain-derived neurotrophic factor is a candidate gene for response to antidepressant treatment. However, response to pharmacological treatments is moderated by both genetic and other factors within individuals. For example, there is evidence of an influence of the temperamental trait of harm avoidance on the outcome of depressive disorders. In the present study we aimed to investigate the effect of the brain-derived neurotrophic factor gene on medium-term outcome in a naturalistic sample of 86 depressed bipolar spectrum patients, taking into account harm avoidance.
Both single marker and haplotypes were significantly associated with severity of depression at month 6 after treatment initiation. The haplotype comprising the A-C alleles was associated with a poorer outcome. Harm avoidance maintained a significant effect on depressive outcome in bipolar disorder, independently from brain-derived neurotrophic factor genotypes. However, harm avoidance s influence appeared to be more consistent in patients carrying the protective G-T combination of alleles.
Our results indicate brain-derived neurotrophic factor as involved in the outcome of depression in bipolar disorder. Harm avoidance did not interact with brain-derived neurotrophic factor genotypes, though its effect was still significant. Given that many factors may influence response to pharmacological treatments, studies that consider personality and other individual characteristics are warranted also in pharmacogenetic investigations.
Akiskal HS, Djenderedjian AM, Rosenthal RH, et al. (1977) Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry134: 1227-1233.
2.
Ashe PC, Berry MD, Boulton AA ( 2001) Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog Neuropsychopharmacol Biol Psychiatry25: 691-707.
3.
Aydemir O., Deveci A., Taneli F. ( 2005) The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry29: 261-265.
4.
Benmansour S., Deltheil T., Piotrowski J., et al. (2008) Influence of brain-derived neurotrophic factor (BDNF) on serotonin neurotransmission in the hippocampus of adult rodents . Eur J Pharmacol587: 90-98.
5.
Chen ZY, Jing D., Bath KG, et al. (2006) Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science314: 140-143.
6.
Choi MJ, Kang RH, Lim SW, et al. (2006) Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res1118: 176-182.
7.
Cloninger CR ( 1987) A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry44: 573-588.
Craddock N., Jones I. ( 1999) Genetics of bipolar disorder. J Med Genet36: 585-594.
10.
Crum RM, Anthony JC, Bassett SS, et al. (1993) Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA269: 2386-2391.
11.
Daws LC, Munn JL, Valdez MF, et al. (2007) Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. J Neurochem101: 641-651.
12.
Drago A., De Ronchi D., Serretti A (2009) Pharmacogenetics of antidepressant response: an update. Hum Genomics3: 257-274.
Duman RS, Malberg J., Thome J. ( 1999) Neural plasticity to stress and antidepressant treatment . Biol Psychiatry46: 1181-1191.
15.
Egan MF, Kojima M., Callicott JH, et al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell112: 257-269.
16.
Fan J., Sklar P. ( 2008) Genetics of bipolar disorder: focus on BDNF Val66Met polymorphism . Novartis Found Symp289: 60-72; discussion 72-73, 87-93.
17.
Faul F. ( 2007) G*Power. Universitat Kiel, Germany.
18.
First MB, Spitzer RL, Gibbon M., et al. (1990) Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). New York: Biometrics Research Department, New York State Psychiatric Institute.
19.
First MB, Spitzer RL, Gibbon M. et al. (1990) Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID - I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute.
20.
Gervasoni N., Aubry JM, Bondolfi G., et al. (2005) Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode . Neuropsychobiology51: 234-238.
21.
Gonul AS, Akdeniz F., Taneli F., et al. (2005) Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci255: 381-386.
22.
Gratacos M., Soria V., Urretavizcaya M., et al. (2008) A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders . Pharmacogenomics J8: 101-112.
23.
Hamilton M. ( 1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56-62.
24.
Jaffee SR, Price TS ( 2007) Gene-environment correlations: a review of the evidence and implications for prevention of mental illness. Mol Psychiatry12: 432-442.
25.
Kang R., Chang H., Wong M., et al. (In press) Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol.
26.
Kato M., Serretti A. (In press) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry.
27.
Kaufman J., Yang BZ, Douglas-Palumberi H., et al. (2006) Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry59: 673-680.
28.
Licinio J., Dong C., Wong ML (2009) Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry66: 488-497.
29.
Lin PI, Vance JM, Pericak-Vance MA, et al. (2007) No gene is an island: the flip-flop phenomenon . Am J Hum Genet80: 531-538.
30.
Lu B., Martinowich K. ( 2008) Cell biology of BDNF and its relevance to schizophrenia . Novartis Found Symp289: 119-129; discussion 129-135, 193-195.
31.
Mamounas LA, Altar CA, Blue ME, et al. (2000) BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci20: 771-782.
32.
Mandelli L., Mazza M., Di Nicola M., et al. (unpublished) The role of substance abuse comorbidity and personality on the outcome of depression in bipolar disorder.
33.
Mandelli L., Mazza M., Martinotti G., et al. (2009) Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients. J Affect Disord119: 205-209.
34.
Martinotti G., Mandelli L., Di Nicola M., et al. (2008) Psychometric characteristic of the Italian version of the Temperament and Character Inventory-Revised (TCI-R). Personality, psychopathology and attachment styles. Compr Psychiatry49: 514-522.
35.
Masui T., Hashimoto R., Kusumi I., et al. (2006) Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr Genet16: 49-50.
36.
Mazza M., Mandelli L., Di Nicola M., et al. (2009) Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. J Affect Disord115: 27-35.
37.
NCBI Entrez SNP. Available at: http://www.ncbi.nlm.nih.gov/sites/entrez?db¼snp
38.
Nibuya M., Morinobu S., Duman RS ( 1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci15: 7539-7547.
39.
Pelissolo A., Corruble E. ( 2002) Personality factors in depressive disorders: contribution of the psychobiologic model developed by Cloninger. Encephale28: 363-373.
40.
Piccinni A., Marazziti D., Catena M., et al. (2008) Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments . J Affect Disord105: 279-283.
41.
R Project for Statistical Computing. Available at: http://www.r-project.org/
42.
Rybakowski JK, Suwalska A., Skibinska M., et al. (2007a) Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet144: 820-823.
43.
Rybakowski JK, Suwalska A., Skibinska M., et al. (2007b) Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet144B: 820-823.
44.
Rybakowski JK, Suwalska A., Skibinska M., et al. (2005) Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry38: 166-170.
45.
Sackeim HA ( 2001) The definition and meaning of treatment-resistant depression . J Clin Psychiatry62(Suppl 16): 10-17.
46.
Serretti A., Kato M., Kennedy JL ( 2008) Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J8: 90-100.
47.
Serretti A., Mandelli L. ( 2008) The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions. Mol Psychiatry13: 742-771.
48.
Shimizu E., Hashimoto K., Okamura N., et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants . Biol Psychiatry54: 70-75.
49.
Tramontina JF, Andreazza AC, Kauer-Sant’anna M., et al. (2009) Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett452: 111-113.
50.
Tsai SJ, Cheng CY, Yu YW, et al. (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet123B: 19-22.
51.
Wilkie MJ, Smith D., Reid IC, et al. (2007) A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics17: 207-215.
52.
Yoshida K., Higuchi H., Kamata M., et al. (2007) The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol21: 650-656.
